Mineralys Therapeutics prices $150 million public offering of common stock

Corporate Action
โดย Insider Monkey·Read original
Summary · why it matters

Mineralys Therapeutics has priced an underwritten public offering of approximately 5.66 million shares of its common stock at $26.50 per share, expecting to generate roughly $150 million in gross proceeds. The offering is scheduled to close on or about June 4, subject to customary closing conditions. The company intends to use the net proceeds to fund a significant portion of a $200 million upfront payment required to repurchase royalty obligations under its existing license agreement with Tanabe Pharma Corporation. This follows a separate announcement of a new $500 million committed debt facility with funds managed by Pharmakon Advisors, LP. BofA Securities, Goldman Sachs & Co. LLC, and Evercore ISI are serving as joint book-running managers for the transaction, which is being conducted under an existing shelf registration statement.

Impact on stocks 3

Financials▲ · 2 stocks
Health Care▼ · 1 stocks

Off-coverage companies 2

Mitsubishi Tanabe Pharma CorporationPrivate▲ Positive
Capitalrelevance

Mineralys will use offering proceeds to repurchase royalty obligations from Tanabe, providing a $200M upfront payment.

Pharmakon Advisors, LPPrivate▲ Positive
Capitalrelevance

Pharmakon Advisors provides a $500M committed debt facility to Mineralys, generating fee income and interest.

© 2026 MarketDXNews